Doo-Il Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Doo-Il Kim has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Dong-Soo Kim
Division of Cardiology, Department of Internal Medicine, Inje University College of Medicine, Busan Paik Hospital, Busan, Korea
4 shared publicationsSang-Hoon Seol
Division of Cardiology, Department of Internal Medicine, Inje University College of Medicine, Busan Paik Hospital, Busan, Korea
4 shared publicationsTae-Hyun Yang
Division of Cardiology, Department of Internal Medicine, Inje University College of Medicine, Busan Paik Hospital, Busan, Korea
4 shared publicationsUng Kim
Division of Cardiology, Department of Internal Medicine, Inje University College of Medicine, Busan Paik Hospital, Busan, Korea
4 shared publicationsDae-Kyeong Kim
Department of Medicine, Inje University College of Medicine, Busan Paik Hospital, Busan, Korea
3 shared publicationsHwan-Jin Cho
Division of Cardiology, Department of Internal Medicine, Ulsan Hospital, Ulsan, Korea
2 shared publications
Latest Publications
- Open Access
- 1 January 2010
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 40 (10) , 527-529
Successful Percutaneous Coronary Intervention for Acute Coronary Syndrome in a Patient With Severe Hemophilia A
Kim DK, et al. Korean Circ J. 2010 Oct;40(10):527-529. http://dx.doi.org/10.4070/kcj.2010.40.10.527
- 1 January 2010
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 40 (10) , 527-529
Open AccessSuccessful Percutaneous Coronary Intervention for Acute Coronary Syndrome in a Patient With Severe Hemophilia A
Kim DK, et al. Korean Circ J. 2010 Oct;40(10):527-529. http://dx.doi.org/10.4070/kcj.2010.40.10.527
- Open Access
- 9 September 2009
- Published by Wiley in Clinical Cardiology
- Vol. 32 (9) , 526-529
Long‐Term Clinical Outcomes After Angiographically Defined Very Late Stent Thrombosis of Drug‐Eluting Stent
Background The advent of drug‐eluting stent (DES) use has raised concerns regarding later occurring stent thrombosis, especially very late stent thrombosis (VLST), and little is known about long‐term clinical outcomes after VLST occurrence. Hypothesis Long‐term clinical outcomes after detection of VLST may be poor. Method We evaluated 3572 consecutive patients who received DES implantation from May 2004 to July 2007 at 3 hospitals. The primary outcomes were a composite of major adverse cardiac events (MACE) including cardiac death, myocardial infarction (MI), target‐lesion revascularization (TLR), and target‐vessel revascularization (TVR) after VLST occurrence. Results We identified 19 patients (0.53%) with angiographically documented stent thrombosis developing over 1 year after DES implantation. The mean time to VLST occurrence was 899 days (899 ± 353). Discontinuation of antiplatelet drugs was noted in 4 (21%) patients and the average duration of discontinuation was 4 days. Clinical presentations of VLST were mainly MI (17 patients, 89%). Balloon angioplasty was only performed in 12 patients (63%) and stent implantation in 7 patients (37%). Mean follow‐up duration from VLST occurrence was 620 days (620±256). During clinical follow‐up after VLST occurrence, no cardiac deaths or MIs were detected. Target‐vessel revascularization was done in 2 (11%) patients and TLR in 1 patient (6%). Major adverse cardiac events occurred in 3 (16%) patients during long‐term clinical follow‐up. Conclusions Clinical presentation of VLST after DES implantation is associated with serious adverse events, such as MI. Long‐term follow‐up outcomes after VLST occurrence appear unfavorable and more data from larger studies are warranted. Copyright
- 9 September 2009
- Published by Wiley in Clinical Cardiology
- Vol. 32 (9) , 526-529
Open AccessLong‐Term Clinical Outcomes After Angiographically Defined Very Late Stent Thrombosis of Drug‐Eluting Stent
Background The advent of drug‐eluting stent (DES) use has raised concerns regarding later occurring stent thrombosis, especially very late stent thrombosis (VLST), and little is known about long‐term clinical outcomes after VLST occurrence. Hypothesis Long‐term clinical outcomes after detection of VLST may be poor. Method We evaluated 3572 consecutive patients who received DES implantation from May 2004 to July 2007 at 3 hospitals. The primary outcomes were a composite of major adverse cardiac events (MACE) including cardiac death, myocardial infarction (MI), target‐lesion revascularization (TLR), and target‐vessel revascularization (TVR) after VLST occurrence. Results We identified 19 patients (0.53%) with angiographically documented stent thrombosis developing over 1 year after DES implantation. The mean time to VLST occurrence was 899 days (899 ± 353). Discontinuation of antiplatelet drugs was noted in 4 (21%) patients and the average duration of discontinuation was 4 days. Clinical presentations of VLST were mainly MI (17 patients, 89%). Balloon angioplasty was only performed in 12 patients (63%) and stent implantation in 7 patients (37%). Mean follow‐up duration from VLST occurrence was 620 days (620±256). During clinical follow‐up after VLST occurrence, no cardiac deaths or MIs were detected. Target‐vessel revascularization was done in 2 (11%) patients and TLR in 1 patient (6%). Major adverse cardiac events occurred in 3 (16%) patients during long‐term clinical follow‐up. Conclusions Clinical presentation of VLST after DES implantation is associated with serious adverse events, such as MI. Long‐term follow‐up outcomes after VLST occurrence appear unfavorable and more data from larger studies are warranted. Copyright
- Open Access
- 4 September 2009
- Published by Springer Nature in Cardiovascular Ultrasound
- Vol. 7 (1) , 1-3
Nonsurgical management of a tricuspid valvular pedunculated papillary fibroelastoma
A 25-year-old woman with a history of kidney transplantation for lupus nephritis was referred for the evaluation and management of a mass incidentally found on echocardiography. An oval and pedunculated mass attached to the tricuspid valve was managed with nonsurgical treatment. No symptoms and complications attributable to the mass developed. Three years later, the size of the mass decreased. Here we report the case of a probable cardiac papillary fibroelastoma (PFE), a mobile mass, with a stalk on the septal leaflet of the tricuspid valve that was managed for three years without surgical treatment.
- 4 September 2009
- Published by Springer Nature in Cardiovascular Ultrasound
- Vol. 7 (1) , 1-3
Open AccessNonsurgical management of a tricuspid valvular pedunculated papillary fibroelastoma
A 25-year-old woman with a history of kidney transplantation for lupus nephritis was referred for the evaluation and management of a mass incidentally found on echocardiography. An oval and pedunculated mass attached to the tricuspid valve was managed with nonsurgical treatment. No symptoms and complications attributable to the mass developed. Three years later, the size of the mass decreased. Here we report the case of a probable cardiac papillary fibroelastoma (PFE), a mobile mass, with a stalk on the septal leaflet of the tricuspid valve that was managed for three years without surgical treatment.
- Open Access
- 1 January 2009
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 39 (10) , 439-442
Multiple Sequential Complications After Sirolimus-Eluting Stent Implantation: Very Late Stent Thrombosis, Stent Fracture, In-Stent Restenosis, and Peri-Stent Aneurysm
Seol SH, et al. Korean Circ J. 2009 Oct;39(10):439-442. http://dx.doi.org/10.4070/kcj.2009.39.10.439
- 1 January 2009
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 39 (10) , 439-442
Open AccessMultiple Sequential Complications After Sirolimus-Eluting Stent Implantation: Very Late Stent Thrombosis, Stent Fracture, In-Stent Restenosis, and Peri-Stent Aneurysm
Seol SH, et al. Korean Circ J. 2009 Oct;39(10):439-442. http://dx.doi.org/10.4070/kcj.2009.39.10.439
- Open Access
- 1 January 2009
- Published by XMLink in Korean Circulation Journal
- Vol. 39 (10) , 408-413
Therapeutic Strategy for In-Stent Restenosis Based on the Restenosis Pattern After Drug-Eluting Stent Implantation
Kim KH, et al. Korean Circ J. 2009 Oct;39(10):408-413. https://doi.org/10.4070/kcj.2009.39.10.408
- 1 January 2009
- Published by XMLink in Korean Circulation Journal
- Vol. 39 (10) , 408-413
Open AccessTherapeutic Strategy for In-Stent Restenosis Based on the Restenosis Pattern After Drug-Eluting Stent Implantation
Kim KH, et al. Korean Circ J. 2009 Oct;39(10):408-413. https://doi.org/10.4070/kcj.2009.39.10.408
- Open Access
- 1 January 2007
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 37 (7) , 304-311
Effects of Cilostazol on the Drug-Eluting Stent in Native Coronary Arteries
Kim SM, et al. Korean Circ J. 2007 Jul;37(7):304-311. http://dx.doi.org/10.4070/kcj.2007.37.7.304
- 1 January 2007
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 37 (7) , 304-311
Open AccessEffects of Cilostazol on the Drug-Eluting Stent in Native Coronary Arteries
Kim SM, et al. Korean Circ J. 2007 Jul;37(7):304-311. http://dx.doi.org/10.4070/kcj.2007.37.7.304